CVS Health Sees Momentum in HCB Segment Amid Utilization Pressure

CVS Health reported strong Q2 2025 results for its Health Care Benefits segment, with revenue up over 11% and adjusted operating income jumping nearly 40%, largely driven by government businesses benefiting from the Inflation Reduction Act. While the company is strategically exiting the individual exchange market in 2026 due to anticipated losses and recorded a $471 million premium deficiency reserve for Group Medicare Advantage, its shares have significantly outperformed the industry over the past year and trade at a lower forward earnings multiple, reflecting bullish earnings estimates and underlying operational strength.

Analysis

CVS Health's Health Care Benefits segment demonstrated robust Q2 2025 performance, with revenue growing over 11% to more than $36 billion and adjusted operating income increasing by nearly 40%. This growth was primarily fueled by its government businesses, which benefited from the Inflation Reduction Act's impact on Medicare Part D, and favorable risk adjustment estimates. However, the company faces specific headwinds, including a $471 million premium deficiency reserve (PDR) for its Group Medicare Advantage line, which elevated the medical benefit ratio to 89.9%, a 30-basis-point increase year-over-year. Strategically, CVS is exiting the unprofitable individual exchange business by 2026, a move that acknowledges projected 2025 losses of $350 million to $400 million from the unit. Despite a sequential drop in medical membership to 26.7 million, the stock has significantly outperformed the industry over the past year, rising 27.5% against the sector's 16.7% decline. This outperformance is supported by a valuation that appears attractive, with the stock trading at a forward earnings multiple of 10.65 compared to the industry average of 15.33, and bullish consensus earnings estimates for 2025 and 2026.

Key Decisions for Investors

• Investors should consider the combination of strong Health Care Benefits segment performance and a valuation discount relative to the industry as a potentially attractive entry or add-on point, supported by bullish forward earnings estimates.
• It is critical to monitor the medical benefit ratio and any future premium deficiency reserves, as the $471 million PDR in Group Medicare Advantage indicates a specific area of margin pressure that could impact future profitability.
• The strategic decision to exit the unprofitable individual exchange market by 2026 should be viewed as a positive long-term catalyst for improving margins and streamlining operations, despite the recognition of near-term losses from the business.
• Given CVS's significant stock outperformance and fundamental strength compared to peers like Elevance Health, which faces its own Medicaid membership pressures, a relative value trade or an overweight position within a healthcare portfolio could be warranted.